JAK2 and cancer: Evidently, there are other ongoing investigations exploring diversely capped HDAC-6 inhibitors for multi-target (e.g., Janus kinase 2 or JAK2 and heat shock protein 90 or Hsp90) activities as potential synergistic pharmacotherapeutic agents for disparate diseases (e.g., fungal and cancer) [21,22,23].